DBVT News and Press, DBV Technologies S.A. From 06/07/22

U.S.-listed shares of DBV Technologies (NASDAQ:DBVT) soared nearly 40% to $2.14 in Tuesday aftermarket trading, after the company said its phase 3 trial assessing its Viaskin Peanut for the treatment of peanut allergies in toddlers aged 1 to 3 years met its main goal. Viaskin Peanut...

Gainers: DBV Technologies  (DBVT) +48%. Biodesix (BDSX) +15%. Intel Corporation (INTC) +7%. Limoneira (LMNR) +6%. Groupon (GRPN) +5%. Losers: Redbox Entertainment (RDBX) -5%. C4 Therapeutics (CCCC) -5%. Kezar Life Sciences (KZR) -5%. Iris Energy Limited (IREN) -5%. LumiraDx Lim...

Montrouge, France, June 7, 2022 DBV Technologies Announce s Positive Topline Results from Phase 3 EPITOPE T rial of Viaskin Peanut in Peanut - Allerg ic Toddlers 67.0% of subjects treated with Viaskin Peanut 250 µ...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE E...

Montrouge, France, May 12, 2022 DBV Technologies Announces Results of I ts 2022 Ordinary and Extraordinary General Meeting Shareholders A pprove d A ll P roposed Re solutions DBV Technologies (Euronext: DBV – ISI...

Montrouge, France, May 5, 2022 DBV Technologies Completes ADSs Sale of an amount of $ 15.3 million on Nasdaq through its At-The-Market program (ATM) DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT) (the “C...

3 Hot Penny Stocks to Add to Your Watchlist Right Now Recently, we’ve seen major volatility with both penny stocks and blue chips. While volatility can be used as an advantage, for those without a well-thought-out trading strategy, it can be detrimental. If you’re inte...

DBV Technologies S.A. (DBVT) Q1 2022 Results Conference Call May 02, 2022 05:00 PM ET Company Participants Anne Pollak - Head, IR Daniel Tassé - CEO Conference Call Participants Jon Wolleben - JMP Securities Presentation Operator Welcome to the DBV Technologies First Quarter 2022 Earning...

Montrouge, France, May 2, 2022 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT) (the “Company”), a clinical-stage biotechnological company, ...

DBV Technologies press release (NASDAQ:DBVT): Q1 GAAP EPS of -$0.30 beats by $0.10. Revenue of $2.55M (-13.3% Y/Y) beats by $1.27M. For further details see: DBV Technologies GAAP EPS of -$0.30 beats by $0.10, revenue of $2.55M beats by $1.27M